Abbott Laboratories (NYSE:ABT) shares came under pressure after the company on Thursday reported a sales miss for the fourth quarter and announced an “underwhelming” revenue guidance for 2026, according to BTIG.
• What’s next for ABT stock?
The Abbott Laboratories Analyst: Analyst Marie Thibault reiterated a Buy rating, while cutting the price target from $145 to $140.
The Abbott Laboratories Thesis: Nearly all segments of the company missed expectations in the fourth quarter and the Devices business “was not the bright spot …